ES2394258T3 - Formas cristalinas de Nilotinib HCL - Google Patents

Formas cristalinas de Nilotinib HCL Download PDF

Info

Publication number
ES2394258T3
ES2394258T3 ES09752057T ES09752057T ES2394258T3 ES 2394258 T3 ES2394258 T3 ES 2394258T3 ES 09752057 T ES09752057 T ES 09752057T ES 09752057 T ES09752057 T ES 09752057T ES 2394258 T3 ES2394258 T3 ES 2394258T3
Authority
ES
Spain
Prior art keywords
nilotinib hcl
degrees
theta
hcl
nilotinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09752057T
Other languages
English (en)
Spanish (es)
Inventor
Greta Sterimbaum
Sigalit Levi
Adi Yeori
Tamas Koltai
Valerie Niddam-Hildesheim
Maytal Piran
Shay Asis
Hagit Eisen-Nevo
David Malcolm Crowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41666779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2394258(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of ES2394258T3 publication Critical patent/ES2394258T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Exhaust Gas Treatment By Means Of Catalyst (AREA)
ES09752057T 2008-11-05 2009-11-05 Formas cristalinas de Nilotinib HCL Active ES2394258T3 (es)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US11156108P 2008-11-05 2008-11-05
US111561P 2008-11-05
US15578909P 2009-02-26 2009-02-26
US155789P 2009-02-26
US17745409P 2009-05-12 2009-05-12
US177454P 2009-05-12
US22721009P 2009-07-21 2009-07-21
US227210P 2009-07-21
US24070909P 2009-09-09 2009-09-09
US240709P 2009-09-09
US24251409P 2009-09-15 2009-09-15
US242514P 2009-09-15
US24679909P 2009-09-29 2009-09-29
US246799P 2009-09-29
US24937609P 2009-10-07 2009-10-07
US249376P 2009-10-07
PCT/US2009/063365 WO2010054056A2 (en) 2008-11-05 2009-11-05 Nilotinib hci crystalline forms

Publications (1)

Publication Number Publication Date
ES2394258T3 true ES2394258T3 (es) 2013-01-30

Family

ID=41666779

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09752057T Active ES2394258T3 (es) 2008-11-05 2009-11-05 Formas cristalinas de Nilotinib HCL

Country Status (12)

Country Link
US (2) US8227477B2 (cg-RX-API-DMAC7.html)
EP (2) EP2530081A3 (cg-RX-API-DMAC7.html)
JP (1) JP5486012B2 (cg-RX-API-DMAC7.html)
KR (2) KR20120111743A (cg-RX-API-DMAC7.html)
CN (1) CN102203084B (cg-RX-API-DMAC7.html)
CA (1) CA2740794A1 (cg-RX-API-DMAC7.html)
DK (1) DK2262793T3 (cg-RX-API-DMAC7.html)
ES (1) ES2394258T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120793T1 (cg-RX-API-DMAC7.html)
PL (1) PL2262793T3 (cg-RX-API-DMAC7.html)
TW (1) TW201022240A (cg-RX-API-DMAC7.html)
WO (1) WO2010054056A2 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011086541A1 (en) * 2010-01-15 2011-07-21 Generics [Uk] Limited Novel polymorph of nilotinib monohydrochloride monohydrate
US20110263701A1 (en) * 2010-04-21 2011-10-27 Sigal Blau Gabapentin enacarbil compositions
EP2571863B1 (en) 2010-06-21 2015-09-23 Teva Pharmaceutical Industries Ltd. Nilotinib salts and crystalline forms thereof
CN103038227A (zh) * 2010-06-21 2013-04-10 特瓦制药工业有限公司 尼洛替尼盐及其晶形
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
WO2012070062A2 (en) * 2010-11-26 2012-05-31 Hetero Research Foundation Novel polymorph of nilotinib hydrochloride
WO2012164578A1 (en) * 2011-06-02 2012-12-06 Hetero Research Foundation Compositions and methods for preparing immediate release formulations of nilotinib
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
ES2564969T3 (es) * 2012-02-09 2016-03-30 Natco Pharma Limited Proceso para la preparación de clorhidrato de nilotinib
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
EP2906554A4 (en) * 2012-10-15 2016-06-29 Apotex Inc SOLID FORMS OF NILOTINIB HYDROCHLORIDE
US9567317B2 (en) 2012-10-19 2017-02-14 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
BR112015026827A2 (pt) 2013-04-24 2017-09-05 Dr Reddy´S Laboratories Ltd Formas polimórficas de cloridrato de nilotinibe
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
WO2016020891A1 (en) 2014-08-08 2016-02-11 Dr. Reddy’S Laboratories Limited Process for the preparation of polymorphic forms of nilotinib
US10016423B2 (en) 2014-10-16 2018-07-10 Apotex Inc. Solid forms of nilotinib hydrochloride
CN106478603B (zh) * 2015-08-25 2021-01-01 江苏豪森药业集团有限公司 尼洛替尼盐酸盐的新晶型及其制备方法和医药用途
EA036204B1 (ru) * 2015-10-16 2020-10-14 Нобел Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции нилотиниба гидрохлорида
WO2017129694A1 (en) 2016-01-26 2017-08-03 Farma Grs, D.O.O. Nilotinib dinitrate (v) and crystalline forms thereof
HUE050890T2 (hu) 2016-03-14 2021-01-28 Pliva Hrvatska D O O Nilotinib sók szilárd halmazállapotú formái
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
EP3806858A4 (en) * 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
US12065426B2 (en) * 2018-11-05 2024-08-20 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
EP4355306A1 (en) 2021-06-19 2024-04-24 Helm AG Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
MY146795A (en) 2005-06-09 2012-09-28 Novartis Ag Process for the synthesis of organic compounds
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
CN101228150B (zh) * 2005-07-20 2014-10-15 诺华股份有限公司 4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的晶形
KR100674813B1 (ko) 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
FR2889524B1 (fr) 2005-08-05 2008-08-29 Rhodia Chimie Sas Procede de formation d'une liaison carbone-azote
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof

Also Published As

Publication number Publication date
EP2530081A3 (en) 2013-04-10
US20130096304A1 (en) 2013-04-18
US20100190812A1 (en) 2010-07-29
US8592442B2 (en) 2013-11-26
JP5486012B2 (ja) 2014-05-07
KR101251726B1 (ko) 2013-04-05
DK2262793T3 (da) 2012-10-15
EP2262793B1 (en) 2012-10-03
US8227477B2 (en) 2012-07-24
CA2740794A1 (en) 2010-05-14
CN102203084A (zh) 2011-09-28
HRP20120793T1 (hr) 2012-12-31
CN102203084B (zh) 2014-10-29
PL2262793T3 (pl) 2013-01-31
TW201022240A (en) 2010-06-16
JP2012508178A (ja) 2012-04-05
EP2262793A2 (en) 2010-12-22
EP2530081A2 (en) 2012-12-05
KR20100099257A (ko) 2010-09-10
WO2010054056A2 (en) 2010-05-14
KR20120111743A (ko) 2012-10-10
WO2010054056A3 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
ES2394258T3 (es) Formas cristalinas de Nilotinib HCL
CN104797566B (zh) 沃替西汀氢溴酸盐的新结晶形式
US20110021567A1 (en) Preparation of lenalidomide
US10023577B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
CN106661015B (zh) 达沙替尼盐
US10150770B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
CN102405219A (zh) 用于治疗copd的5-吡唑基-2-吡啶酮衍生物的对甲苯磺酸盐
US20150038721A1 (en) Solid forms of dabigatran etexilate mesylate and processes for their preparation
CN105408329A (zh) 呈晶体形式的达沙替尼的盐
WO2009049495A1 (en) Crystalline imidazol-5-carboxylic acid derivate
CN109438370B (zh) 一种甲基吡嗪衍生物无水晶型
CN101663314A (zh) D-异谷氨酰基-d-色氨酸的一钠盐的晶态形式
JP2007527924A (ja) 非晶質バルサルタンの製造方法
US20240293420A1 (en) Pharmaceutical composition, preparation, and preparation method therefor and use thereof
WO2011152411A1 (ja) チエノピリミジン誘導体の結晶
WO2018042320A1 (en) Salts of betrixaban and processes for preparation thereof
US20060100432A1 (en) Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
KR101423630B1 (ko) 비칼루타미드와 니코틴아미드의 공결정
ES2327265T3 (es) Una nueva forma cristalina estable de andolast.
KR20130033242A (ko) 클로피도그렐의 공결정
JP2010180169A (ja) アミド化合物の結晶
US20060270685A1 (en) Anhydrous ziprasidone mesylate and a process for its preparation
KR20130033243A (ko) 아데포비어 디피복실의 공결정
WO2015113314A1 (zh) 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法
SK288226B6 (sk) Kryštalická alfa-forma Imatinib mezylátu s novým habitom a spôsob jeho prípravy a použitie